Kinnate Biopharma is designing and developing selective small molecules to target various cancers. Kinases are a class of proteins that are effective targeting nodes in cancer, but have been hard to target selectively with drugs. Kinate is using structure-based drug discovery and translational research to design molecules with high selectivity, optimized pharmaceutical properties, broad coverage of genetic alterations for different genetic changes in cancer cells, and the ability to overcome resistance or penetrate the brain. Using this stringent drug selection approach, with their well-defined patient populations, Kinnate hopes to streamline the development process and increase their chances of success.

Kinnate Biopharma

Short description:

Drug notes:

Long description:

Jobs: